36,800 Shares in United Therapeutics Corporation $UTHR Purchased by Empowered Funds LLC

Empowered Funds LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 36,800 shares of the biotechnology company’s stock, valued at approximately $19,939,000. Empowered Funds LLC owned 0.09% of United Therapeutics as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the business. Torren Management LLC purchased a new position in United Therapeutics during the 4th quarter valued at about $26,000. Fiduciary Financial Advisors purchased a new stake in United Therapeutics during the 2nd quarter worth approximately $30,000. Activest Wealth Management increased its stake in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the period. Entrust Financial LLC purchased a new stake in shares of United Therapeutics during the fourth quarter worth $31,000. Finally, Caitlin John LLC acquired a new stake in shares of United Therapeutics in the second quarter valued at $37,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $517.28, for a total value of $4,914,160.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $167,827,875.04. This represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $23,631,280.08. The trade was a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 424,075 shares of company stock valued at $227,336,485 over the last three months. Company insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Royal Bank Of Canada cut their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Stock Performance

UTHR opened at $527.91 on Friday. United Therapeutics Corporation has a one year low of $302.19 and a one year high of $609.35. The company has a market cap of $22.64 billion, a P/E ratio of 18.89, a PEG ratio of 1.75 and a beta of 0.59. The business’s 50-day simple moving average is $530.89 and its 200-day simple moving average is $538.86.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the previous year, the business earned $6.41 earnings per share. The firm’s revenue was down 1.9% compared to the same quarter last year. As a group, analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.